Prevalence of active tuberculosis infection in transplant recipients: A systematic review and meta-analysis

Mamishi, Setareh; Pourakbari, Babak; Moradzadeh, Mina; Leeuwen, Willem B. van; Mahmoudi, Shima

doi:10.1016/j.micpath.2019.103894

Cited by 18 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to 95% of active TB cases occur within the first-year post-transplant, with 50–76% of these cases involving the lungs. 3 , 7 – 9 Lung transplant recipients are at greater risk of graft TB infection as the lung is the primary site of infection. 3 , 10 – 12 Disseminated infection is associated with higher mortality 4 , 13 and occurs in 22–39% of transplant recipients with active TB, 6 – 8 a stark contrast with the relatively low incidence of disseminated infection in the general population.…”

Section: Discussionmentioning

confidence: 99%

Disseminated tuberculosis in a lung transplant recipient presenting as tenosynovitis, subcutaneous nodules, and liver abscesses

Barahona

Henao-Cordero

Smith

et al. 2022

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Tuberculosis is of particular concern in lung transplant recipients. We present the case of a patient who received a double lung transplant from a deceased donor from Mexico and developed disseminated tuberculosis 60 days post-transplant manifested as tenosynovitis, liver abscesses, and subcutaneous nodules with no definitive lung allograft involvement. The recipient did not have evidence of tuberculosis on explanted lungs, had a negative interferon gamma release assay pre-transplant, and did not have risk factors for this infection. Mycobacterium tuberculosis should remain in the differential diagnosis of early post-transplant infections with atypical presentations, evidence of dissemination, or lack of improvement with appropriate antimicrobial coverage, even in the absence of typical lung findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Disseminated tuberculosis in a lung transplant recipient presenting as tenosynovitis, subcutaneous nodules, and liver abscesses

Barahona

Henao-Cordero

Smith

et al. 2022

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

“…TB is associated with mortality as high as 10 to 20%, although rates are decreasing possibly due to heightened clinical suspicion and optimization of treatment approaches to minimize and manage drug-drug interactions. 17,18 The American Society of Transplantation recommends that all transplant candidates be screened and treated for latent TB infection (LTBI) before transplant. 19 As outlined in these guidelines, an assessment should include symptom inquiry, a review of epidemiological risk factors, chest radiography, and either a tuberculin skin test (TST) or interferongamma release assay (IGRA).…”

Section: Tuberculosis Latent Tuberculosis-diagnostic and Therapeutic Challengesmentioning

confidence: 99%

Mycobacteria: Selection of Transplant Candidates and Post–lung Transplant Outcomes

Friedman

Doucette

2021

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Mycobacterium is a large, clinically relevant bacterial genus made up of the agents of tuberculosis and leprosy and hundreds of species of saprophytic nontuberculous mycobacteria (NTM). Pathogenicity, clinical presentation, epidemiology, and antimicrobial susceptibilities are exceptionally diverse between species. Patients with end-stage lung disease and recipients of lung transplants are at a higher risk of developing NTM colonization and disease and of severe manifestations and outcomes of tuberculosis. Data from the past three decades have increased our knowledge of these infections in lung transplant recipients. Still, there are knowledge gaps to be addressed to further our understanding of risk factors and optimal treatments for mycobacterial infections in this population.

show abstract

“…( Yang et al, Although recommendations for LTBI treatment do not distinguish between patients according to transplanted organs (Subramanian et al, 2019), the epidemiology of TB in SOT recipients varies from organ to organ. Prior systematic reviews showed that the post-transplant prevalence of active TB in liver transplant (LT) recipients (1%) is the lowest among SOT recipients (compared with 3-4% for heart, and kidney transplant recipients) ( Mamishi et al, 2020 ). In contrast, LT recipients were the most vulnerable to hepatotoxicity with LTBI treatment.…”

Section: Introductionmentioning

confidence: 99%

Risk Groups of Developing Active Tuberculosis in Liver Transplant Recipients in a Tuberculosis Endemic Area: Risk Stratification by Chest Image and Interferon Gamma Release Assay

Kim

Oh²,

Nham

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Prevalence of active tuberculosis infection in transplant recipients: A systematic review and meta-analysis

Cited by 18 publications

References 48 publications

Disseminated tuberculosis in a lung transplant recipient presenting as tenosynovitis, subcutaneous nodules, and liver abscesses

Disseminated tuberculosis in a lung transplant recipient presenting as tenosynovitis, subcutaneous nodules, and liver abscesses

Mycobacteria: Selection of Transplant Candidates and Post–lung Transplant Outcomes

Risk Groups of Developing Active Tuberculosis in Liver Transplant Recipients in a Tuberculosis Endemic Area: Risk Stratification by Chest Image and Interferon Gamma Release Assay

Contact Info

Product

Resources

About